Suppr超能文献

液体活检标志物可预测 T1 期食管鳞癌的淋巴结转移:对精准治疗策略的影响。

A liquid biopsy signature predicts lymph node metastases in T1 oesophageal squamous cell carcinoma: implications for precision treatment strategy.

机构信息

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

State Key Laboratory of Molecular Oncology, Key Laboratory of Cancer and Microbiome, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Br J Cancer. 2022 Nov;127(11):2052-2059. doi: 10.1038/s41416-022-01997-y. Epub 2022 Oct 7.

Abstract

BACKGROUND

The treatment strategies for T1 oesophageal squamous cell carcinoma (ESCC) patients with or without lymph node metastasis (LNM) are different. Given the advantages of the minimally invasive, sensitive and real-time detection, liquid biopsy has become an important cancer diagnostic and prognostic tool.

METHODS

MiRNA array and small-RNA sequencing were performed. Then, 222 formalin-fixed and paraffin-embedded tumour samples and 229 pretreatment serum samples from T1 ESCC patients were used to verify and evaluate the results.

RESULTS

We demonstrated that serum miR-20b-5p could predict LNM in T1 ESCC patients. The AUC for serum miR-20b-5p was higher (0.827) than those for lymphovascular invasion (LVI) (0.751, P = 0.2128), invasion depth (0.662, P = 0.0027) and tumour differentiation grade (0.634, P = 0.0019). A nomogram for predicting LNM with three independent significant predictors (miR-20b-5p, LVI and invasion depth) was constructed with a concordance index of 0.931. Serum miR-20b-5p was also significantly correlated with disease-free survival (P < 0.001). An algorithm of improved T1 ESCC treatment strategy after biopsy and/or after endoscopic resection based on serum miR-20b-5p level was constructed.

CONCLUSIONS

This study suggests that serum miR-20b-5p is a potential biomarker for predicting LNM and can be helpful for precise clinical decision-making strategies and improve treatment outcomes for T1 ESCC patients.

摘要

背景

T1 食管鳞状细胞癌(ESCC)患者伴或不伴淋巴结转移(LNM)的治疗策略不同。鉴于液体活检具有微创、敏感和实时检测的优势,已成为一种重要的癌症诊断和预后工具。

方法

进行 miRNA 阵列和小 RNA 测序。然后,使用 222 例 T1 ESCC 患者的福尔马林固定石蜡包埋肿瘤样本和 229 例治疗前血清样本进行验证和评估。

结果

我们证明了血清 miR-20b-5p 可预测 T1 ESCC 患者的 LNM。血清 miR-20b-5p 的 AUC 高于淋巴血管侵犯(LVI)(0.751,P=0.2128)、浸润深度(0.662,P=0.0027)和肿瘤分化程度(0.634,P=0.0019)。构建了一个包含三个独立显著预测因子(miR-20b-5p、LVI 和浸润深度)的 LNM 预测列线图,其一致性指数为 0.931。血清 miR-20b-5p 与无病生存期显著相关(P<0.001)。基于血清 miR-20b-5p 水平构建了改进的活检后和/或内镜切除后 T1 ESCC 治疗策略的算法。

结论

本研究表明,血清 miR-20b-5p 是预测 LNM 的潜在生物标志物,有助于制定精确的临床决策策略,改善 T1 ESCC 患者的治疗效果。

相似文献

4
Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma.
PLoS One. 2014 Mar 20;9(3):e92292. doi: 10.1371/journal.pone.0092292. eCollection 2014.
7
Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma.
J Gastroenterol Hepatol. 2020 Jun;35(6):1009-1015. doi: 10.1111/jgh.14915. Epub 2019 Dec 15.
8
A novel serum microRNA signature to screen esophageal squamous cell carcinoma.
Cancer Med. 2017 Jan;6(1):109-119. doi: 10.1002/cam4.973. Epub 2016 Dec 30.
9
[Effects of microRNA-182-5p on cell proliferation and invasion of esophageal squamous cell carcinoma and related molecular mechanisms].
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):635-643. doi: 10.3760/cma.j.cn112152-20200310-00191.

引用本文的文献

1
Transcriptome analysis and artificial intelligence for predicting lymph node metastasis of esophageal squamous cell carcinoma.
J Thorac Dis. 2025 May 30;17(5):3283-3296. doi: 10.21037/jtd-2025-662. Epub 2025 May 28.
2
Identification and validation of LINC02381 as a biomarker associated with lymph node metastasis in esophageal squamous cell carcinoma.
Transl Cancer Res. 2025 Jan 31;14(1):613-625. doi: 10.21037/tcr-2024-2402. Epub 2025 Jan 23.
3
Preoperative liquid biopsy transcriptomic panel for risk assessment of lymph node metastasis in T1 gastric cancer.
J Exp Clin Cancer Res. 2025 Feb 7;44(1):43. doi: 10.1186/s13046-025-03305-x.
4
Biomarkers of lymph node metastasis in esophageal cancer.
Front Immunol. 2024 Sep 27;15:1457612. doi: 10.3389/fimmu.2024.1457612. eCollection 2024.
6
miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology.
Rep Pract Oncol Radiother. 2023 Nov 16;28(5):681-697. doi: 10.5603/rpor.96666. eCollection 2023.
7
Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer.
Int J Colorectal Dis. 2022 Nov;37(11):2321-2333. doi: 10.1007/s00384-022-04268-7. Epub 2022 Oct 15.

本文引用的文献

1
A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer.
Gastroenterology. 2021 Jul;161(1):151-162.e1. doi: 10.1053/j.gastro.2021.03.062. Epub 2021 Apr 2.
2
3
Functional Significance and Therapeutic Potential of miRNA-20b-5p in Esophageal Squamous Cell Carcinoma.
Mol Ther Nucleic Acids. 2020 Sep 4;21:315-331. doi: 10.1016/j.omtn.2020.05.015. Epub 2020 Jun 12.
4
A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Gastroenterology. 2020 Aug;159(2):562-574. doi: 10.1053/j.gastro.2020.04.057. Epub 2020 May 4.
6
Esophagectomy after endoscopic submucosal dissection for esophageal carcinoma.
J Thorac Dis. 2018 Jun;10(6):3253-3261. doi: 10.21037/jtd.2018.05.143.
7
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6.
8
Clinical utility of circulating non-coding RNAs - an update.
Nat Rev Clin Oncol. 2018 Sep;15(9):541-563. doi: 10.1038/s41571-018-0035-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验